{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:05:33Z","timestamp":1785222333974,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["Richard Yu CUHK PD Research Fund"],"award-info":[{"award-number":["Richard Yu CUHK PD Research Fund"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04194-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:13:57Z","timestamp":1748265237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intermittent sodium zirconium cyclosilicate for the prevention of hyperkalemia in chronic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Jack Kit-Chung","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston Wing-Shing","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon Chun-Kau","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ming","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk-Chun","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"3","key":"4194_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MNH.0000000000000320","volume":"26","author":"AC Cowan","year":"2017","unstructured":"Cowan AC, Gharib EG, Weir MA. Advances in the management of hyperkalemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(3):235\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 3","key":"4194_CR2","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","volume":"34","author":"RW Hunter","year":"2019","unstructured":"Hunter RW, Bailey MA. Hyperkalemia: Pathophysiology, risk factors and consequences. Nephrol Dial Transpl. 2019;34(Suppl 3):iii2\u201311.","journal-title":"Nephrol Dial Transpl"},{"issue":"7\u20138","key":"4194_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000531102","volume":"54","author":"J An","year":"2023","unstructured":"An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ. Discontinuation of renin-angiotensin-aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes. Am J Nephrol. 2023;54(7\u20138):258\u201367.","journal-title":"Am J Nephrol"},{"issue":"22","key":"4194_CR4","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, Chadburn M, Cockwell P. STOP ACEi trial investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387(22):2021\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"4194_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","volume":"89","author":"RH Sterns","year":"2016","unstructured":"Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: Something old, something new. Kidney Int. 2016;89(3):546\u201354.","journal-title":"Kidney Int"},{"issue":"11","key":"4194_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","volume":"10","author":"CP Kovesdy","year":"2014","unstructured":"Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653\u201362.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"4194_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/phar.1797","volume":"36","author":"KE Linder","year":"2016","unstructured":"Linder KE, Krawczynski MA, Laskey D. Sodium zirconium cyclosilicate (ZS-9): A novel agent for the treatment of hyperkalemia. Pharmacotherapy. 2016;36(8):923\u201333.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"4194_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1358\/dot.2018.54.10.2872504","volume":"54","author":"A Cases","year":"2018","unstructured":"Cases A, Gorriz JL. Sodium zirconium cyclosilicate: A new potassium binder for the treatment of hyperkalemia. Drugs Today (Barc). 2018;54(10):601\u201313.","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"4194_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222\u201331.","journal-title":"N Engl J Med"},{"issue":"9","key":"4194_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/17512433.2021.1932460","volume":"14","author":"A Rastogi","year":"2021","unstructured":"Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent. Expert Rev Clin Pharmacol. 2021;14(9):1055\u201364.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"4194_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/14656566.2022.2161884","volume":"24","author":"Y Lu","year":"2023","unstructured":"Lu Y, Liu BC, Liu H. An evaluation of sodium zirconium cyclosilicate: A new treatment option for hyperkalaemia in China. Expert Opin Pharmacother. 2023;24(3):301\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"21","key":"4194_CR12","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium Lowering for 28 days among outpatients with hyperkalemia: The Harmonize randomized clinical trial. JAMA. 2014;312(21):2223\u201333.","journal-title":"JAMA"},{"issue":"6","key":"4194_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK. ZS-005 study investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: A 12-Month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798\u2013809.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"4194_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/M23-3236","volume":"177","author":"E Ku","year":"2024","unstructured":"Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Hou FF, Toto RD, Li PK, Sarnak MJ. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: A systematic review and retrospective individual participant-level meta-analysis of clinical trials. Ann Intern Med. 2024;177(7):953\u201363.","journal-title":"Ann Intern Med"},{"issue":"2","key":"4194_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/ip.7.2.89","volume":"7","author":"J Adams","year":"2001","unstructured":"Adams J, Hillman M. The risk compensation theory and bicycle helmets. Inj Prev. 2001;7(2):89\u201391.","journal-title":"Inj Prev"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04194-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04194-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04194-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:14:00Z","timestamp":1748265240000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04194-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4194"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04194-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Joint Chinese University Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (approval numbers CRE-2024.178).Written consent of the subjects to participate: waived by the Clinical Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All study procedures were in compliance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standard of research procedures"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}